SG11201905601VA - Scn9a antisense pain killer - Google Patents
Scn9a antisense pain killerInfo
- Publication number
- SG11201905601VA SG11201905601VA SG11201905601VA SG11201905601VA SG11201905601VA SG 11201905601V A SG11201905601V A SG 11201905601VA SG 11201905601V A SG11201905601V A SG 11201905601VA SG 11201905601V A SG11201905601V A SG 11201905601VA SG 11201905601V A SG11201905601V A SG 11201905601VA
- Authority
- SG
- Singapore
- Prior art keywords
- gyeonggi
- yongin
- gil
- giheung
- apt
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title abstract 3
- 230000036407 pain Effects 0.000 title abstract 3
- 230000000692 anti-sense effect Effects 0.000 title abstract 2
- 101150080511 Scn9a gene Proteins 0.000 title 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 abstract 4
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 abstract 3
- 108091093037 Peptide nucleic acid Proteins 0.000 abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract 1
- 108020005067 RNA Splice Sites Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000048004 human SCN9A Human genes 0.000 abstract 1
- 229960004194 lidocaine Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 abstract 1
- 229950010357 tetrodotoxin Drugs 0.000 abstract 1
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762449738P | 2017-01-24 | 2017-01-24 | |
| PCT/IB2018/000160 WO2018138585A1 (en) | 2017-01-24 | 2018-01-23 | Scn9a antisense pain killer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201905601VA true SG11201905601VA (en) | 2019-08-27 |
Family
ID=62979263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201905601VA SG11201905601VA (en) | 2017-01-24 | 2018-01-23 | Scn9a antisense pain killer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11162104B2 (pt) |
| EP (1) | EP3573998A4 (pt) |
| JP (1) | JP7241019B2 (pt) |
| KR (1) | KR102592876B1 (pt) |
| CN (1) | CN110536895B (pt) |
| AU (1) | AU2018213153B2 (pt) |
| BR (1) | BR112019014689A2 (pt) |
| CA (1) | CA3051178A1 (pt) |
| IL (1) | IL267881B2 (pt) |
| MX (1) | MX2019008445A (pt) |
| RU (1) | RU2762293C2 (pt) |
| SG (1) | SG11201905601VA (pt) |
| WO (1) | WO2018138585A1 (pt) |
| ZA (1) | ZA201905064B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3562836A4 (en) * | 2016-12-30 | 2020-08-05 | Olipass Corporation | EXON BREAKDOWN BY NUCLEIC ACID PEPTIDIC DERIVATIVES |
| KR102304280B1 (ko) | 2018-08-14 | 2021-09-23 | 올리패스 주식회사 | 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드 |
| WO2021247995A2 (en) * | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
| WO2022147541A1 (en) * | 2021-01-04 | 2022-07-07 | Exicure Operating Company | Compounds for modulating scn9a expression |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617422B1 (en) * | 1997-05-23 | 2003-09-09 | Peter Nielsen | Peptide nucleic acid monomers and oligomers |
| US9278088B2 (en) * | 2002-02-19 | 2016-03-08 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
| US7060723B2 (en) * | 2003-08-29 | 2006-06-13 | Allergan, Inc. | Treating neurological disorders using selective antagonists of persistent sodium current |
| WO2007109324A2 (en) | 2006-03-21 | 2007-09-27 | Xenon Pharmaceuticals, Inc. | Potent and selective nav 1.7 sodium channel blockers |
| KR101375470B1 (ko) * | 2006-10-20 | 2014-03-27 | 네이쳐웍스 엘엘씨 | 충격 개질된 폴리락타이드 수지 |
| WO2009033027A2 (en) | 2007-09-05 | 2009-03-12 | Medtronic, Inc. | Suppression of scn9a gene expression and/or function for the treatment of pain |
| CN101480393A (zh) * | 2008-01-07 | 2009-07-15 | 云南昊邦制药有限公司 | 草乌甲素作为制备治疗Nav1.7疼痛病症药物的应用 |
| JP5143031B2 (ja) | 2008-01-22 | 2013-02-13 | パナソニック株式会社 | 光ディスクドライブ、光ディスクシステム、光ディスクシステムを搭載した移動体、プログラム、及び記録媒体 |
| KR20090098710A (ko) * | 2008-03-14 | 2009-09-17 | 주식회사 씨티아이바이오 | 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체 |
| WO2009143277A2 (en) * | 2008-05-20 | 2009-11-26 | Intradigm Corporation | Compositions comprising hscn9a sirna and methods of use thereof |
| KR20110087436A (ko) * | 2010-01-26 | 2011-08-03 | 주식회사 씨티아이바이오 | 전위차 나트륨 이온 채널 아형 9(에스씨엔 9에이)의 안티센스 올리고핵산 |
| EP2585596B1 (en) * | 2010-06-23 | 2020-12-30 | CuRNA, Inc. | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
| EA201391331A1 (ru) * | 2011-03-16 | 2014-02-28 | Эмджен Инк. | Активные и селективные ингибиторы nav1.3 и nav1.7 |
| TWI642438B (zh) * | 2011-06-24 | 2018-12-01 | 可娜公司 | 藉由抑制電壓門控鈉離子通道α次單元（ＳＣＮＡ）之天然反義轉錄物治療ＳＣＮＡ相關疾病 |
| WO2018029517A1 (en) | 2016-08-08 | 2018-02-15 | Olipass Corporation | Androgen receptor antisense oligonucleotides |
| WO2018051175A1 (en) | 2016-09-16 | 2018-03-22 | Olipass Corporation | Scn9a antisense oligonucleotides |
| EP3562836A4 (en) | 2016-12-30 | 2020-08-05 | Olipass Corporation | EXON BREAKDOWN BY NUCLEIC ACID PEPTIDIC DERIVATIVES |
-
2018
- 2018-01-23 KR KR1020197023676A patent/KR102592876B1/ko active IP Right Grant
- 2018-01-23 AU AU2018213153A patent/AU2018213153B2/en active Active
- 2018-01-23 MX MX2019008445A patent/MX2019008445A/es unknown
- 2018-01-23 CA CA3051178A patent/CA3051178A1/en active Pending
- 2018-01-23 JP JP2019539749A patent/JP7241019B2/ja active Active
- 2018-01-23 EP EP18744379.1A patent/EP3573998A4/en active Pending
- 2018-01-23 BR BR112019014689-0A patent/BR112019014689A2/pt unknown
- 2018-01-23 WO PCT/IB2018/000160 patent/WO2018138585A1/en unknown
- 2018-01-23 US US16/480,147 patent/US11162104B2/en active Active
- 2018-01-23 SG SG11201905601VA patent/SG11201905601VA/en unknown
- 2018-01-23 RU RU2019125286A patent/RU2762293C2/ru active
- 2018-01-23 IL IL267881A patent/IL267881B2/en unknown
- 2018-01-23 CN CN201880018551.7A patent/CN110536895B/zh active Active
-
2019
- 2019-07-31 ZA ZA2019/05064A patent/ZA201905064B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190338292A1 (en) | 2019-11-07 |
| EP3573998A4 (en) | 2020-12-16 |
| CN110536895B (zh) | 2023-10-20 |
| AU2018213153A1 (en) | 2019-08-15 |
| IL267881B1 (en) | 2023-11-01 |
| WO2018138585A1 (en) | 2018-08-02 |
| RU2019125286A (ru) | 2021-02-26 |
| MX2019008445A (es) | 2020-02-10 |
| US11162104B2 (en) | 2021-11-02 |
| KR102592876B1 (ko) | 2023-10-23 |
| CN110536895A (zh) | 2019-12-03 |
| RU2019125286A3 (pt) | 2021-05-14 |
| JP2020506686A (ja) | 2020-03-05 |
| IL267881B2 (en) | 2024-03-01 |
| BR112019014689A2 (pt) | 2020-02-18 |
| EP3573998A1 (en) | 2019-12-04 |
| RU2762293C2 (ru) | 2021-12-17 |
| ZA201905064B (en) | 2022-10-26 |
| IL267881A (en) | 2019-09-26 |
| JP7241019B2 (ja) | 2023-03-16 |
| AU2018213153B2 (en) | 2021-04-01 |
| KR20190103372A (ko) | 2019-09-04 |
| CA3051178A1 (en) | 2018-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201905601VA (en) | Scn9a antisense pain killer | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201908547VA (en) | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201408124PA (en) | Differentiation of human embryonic stem cells into pancreatic endocrine cells | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804836RA (en) | Treatment of fibrosis | |
| SG11201408307VA (en) | Needle guard | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201407372UA (en) | Nampt inhibitors | |
| SG11201908060PA (en) | Wound healing medicament | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201808964PA (en) | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |